Denosumab Effective for Multiple Myeloma and Solid Tumors

Adapted from the NCI Cancer Bulletin.

Results from a randomized phase III trial of denosumab for cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO). FDA approval of denosumab for the reduction of skeletal-related events (SREs) was based in part on this study.

The nearly 1,800-patient trial had a design similar to that of a separate trial of denosumab for prostate cancer that was reported in The Lancet. It included patients with multiple myeloma and a variety of advanced solid tumors (but specifically excluded patients with prostate and breast cancer). Patients who received denosumab had a reduced risk of SREs compared with patients who received zoledronic acid, although the reduction did not reach statistical significance.

In an accompanying commentary, Howard West, M.D., of the Swedish Cancer Institute in Seattle addressed the economic implications of denosumab treatment, as well as a potential biomarker-driven approach to its use in patients with metastatic cancer.

  • Posted: June 8, 2011

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Denosumab Effective for Multiple Myeloma and Solid Tumors was originally published by the National Cancer Institute.”

We welcome your comments on this post. All comments must follow our comment policy.